Major trial tests new weapon against tough breast cancer cases
NCT ID NCT06830889
Summary
This large study is testing whether a new drug called BL-M07D1 works better than the current standard treatment (T-DM1) for people with a specific type of breast cancer. It's for women with HER2-positive breast cancer who still have some cancer cells left after their initial chemotherapy and surgery. The main goal is to see which treatment is better at keeping the cancer from coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, China
Contact
Conditions
Explore the condition pages connected to this study.